Q3 FY26 results: PAT falls 36% YoY; board approves EUR 3M Singapore infusion, new director

Ebitda Margin CompressionExceptional ItemRelated Party TransactionsResults View source PDF Explain this filing

TARSONS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.9%Reaction day

₹207.01

prior close

₹206.58

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.8%+4.7% vs market

Medical Equipment & Supplies peers, median of 9sector+1.1%+2.7% vs sector

On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 2.7 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.2

10m

+1.8

15m

+1.1

30m

+2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.9-0.8+4.7+1.1+2.7

Next day

+3.4+1.8+1.6+1.7+1.7

+5.3+2.8+2.5+2.2+3.1

+0.4+2.3-1.9+1.4-1.0

-3.1+1.8-4.9+4.3-7.4

-3.9+0.3-4.1+1.5-5.4

-2.2+0.5-2.7+1.6-3.8

15d

-7.5-2.5-5.0-0.7-6.8

-8.4-6.3-2.0-7.3-1.1

-10.8-8.0-2.8-6.7-4.1

+10.2+8.3+2.0+2.5+7.7

UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 9Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Standalone revenue rose 10% YoY to INR 839.9M in Q3 FY26 (9M: INR 2,358M vs INR 2,211M). However, 9M PAT dropped 36% to INR 171.9M (Q3: INR 70.9M vs INR 76.1M) as depreciation surged 66% to INR 605.8M. Board also approved EUR 3M equity infusion in Singapore subsidiary Tarsons Life Science Pte. Ltd., appointed Mr. Vinesh Kriplani as Independent Director, and accepted Mr. Girish Vanvari resignation for personal reasons.

Likely market impact

Revenue grew but sharp profit decline on higher depreciation flags margin pressure. Director change and Singapore arm funding are routine for a growing company.